Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial.
From 97 screened patients, we excluded 67 due to active LN, low proteinuria or low eGFR. Thirty patients were randomized: 14 to start the treatment with dapagliflozin on top of SoC therapy and 16 to remain with the usual therapy for 6 months. Nine patients were excluded from the analysis due to new LN flares or lost to follow-up. We demonstrate a significant reduction in residual proteinuria in patients with inactive LN with dapagliflozin without safety concerns.
Category
Transplant
Source
Nephrology Dialysis Transplantation
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.